Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Metreleptin (FDA/EMA approval under brand name Myalept®) to named patients in CIS (excluding Russia). FarmaMondo will provide a Managed Access service to Amryt including disease awareness activities and will work in collaboration with Amryt medical teams to extend access to unsolicited requests of HCPs in the covered region.
Myalept® (Metreleptin) for injection is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It is the only treatment available to control this rare condition, there are no other affordable alternatives.
Farmamondo is a Swiss-headquartered pharmaceutical group focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to facilitate patient access to medicines across the unlicensed and licensed product phases.
For more information about FarmaMondo please visit www.farmamondo.com.
For all inquiries regarding Myalept®, please contact
Email: email@example.com Phone: +41 91 6976390
About Amryt Pharma
Amryt Pharma is an Irish based biopharma quoted on the London Stock Exchange’s AIM Market and the Irish Stock Exchange’s Euronext Market. Amryt is focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases